INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Corporate insider
SS

Stout Jay S

Chief Technology OfficerCIK 0001702969

EDGAR filingsOpen in network
Disclosed transactions13
Buys / sells0 / 11
Max Insider Score42
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
32
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$75K
2,595 sh
Oct 21, 2026Oct 23, 2026
traded Oct 21, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Immunovant, Inc.Chief Technology Officer · Jan 9, 2026
27
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL
$71K
2,213 sh
Oct 7, 2026
Oct 9, 2026
traded Oct 7, 2026
+2d
SEC FORM 4

Evidence

27
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$51K
1,596 sh
Oct 7, 2026Oct 9, 2026
traded Oct 7, 2026
+2dSEC FORM 4

Evidence

42
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$1.27M
33.3K sh
Jun 26, 2026Jun 26, 2026
traded Jun 26, 2026
+0dSEC FORM 4

Evidence

35
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$262K
6,723 sh
Jun 26, 2026Jun 26, 2026
traded Jun 26, 2026
+0dSEC FORM 4

Evidence

25
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$82K
2,754 sh
Apr 23, 2026Apr 24, 2026
traded Apr 23, 2026
+1dSEC FORM 4

Evidence

27
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$38K
1,518 sh
Apr 8, 2026Apr 10, 2026
traded Apr 8, 2026
+2dSEC FORM 4

Evidence

30
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$214K
8,614 sh
Apr 8, 2026Apr 10, 2026
traded Apr 8, 2026
+2dSEC FORM 4

Evidence

13
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Grant or award
A—
66.9K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

5
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Grant or award
A—
96.9K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

20
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$51K
1,977 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

21
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$30K
1,148 sh
Jan 7, 2026Jan 9, 2026
traded Jan 7, 2026
+2dSEC FORM 4

Evidence

21
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$1,481
55 sh
Jan 7, 2026Jan 9, 2026
traded Jan 7, 2026
+2dSEC FORM 4

Evidence